The main findings are that: (1) RyR2 mutations account for over half of the CPVT cases, (2) 24 RyR2 variants, eight CASQ2 variants, two TERCL variants and one SCN10A variant were described, (3) β-blockers are used in 93.1% of the cases, followed less frequently by flecainide, amiodarone, verapamil and propafenone, and (4) 17.2% patients underwent cardiac sympathectomy, 13.8% received ICDs and 1.7% received ablation. The gene discussed is CASQ2; the disease is catecholaminergic polymorphic ventricular tachycardia.